- Home
- ELVN vs CIM Comparison
ELVN vs CIM Comparison
Compare ELVN & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | CIM |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ELVN | CIM |
|---|---|---|
| Price | $17.85 | $13.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $41.20 | $15.25 |
| AVG Volume (30 Days) | ★ 809.4K | 788.4K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 11.46% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $191,573,000.00 |
| Revenue This Year | N/A | $17.34 |
| Revenue Next Year | N/A | $15.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.30 | $9.85 |
| 52 Week High | $25.37 | $15.37 |
Technical Indicators
Market Signals| Indicator | ELVN | CIM |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 56.81 |
| Support Level | $15.71 | $12.57 |
| Resistance Level | $17.58 | $13.10 |
| Average True Range (ATR) | 1.41 | 0.23 |
| MACD | -0.30 | 0.03 |
| Stochastic Oscillator | 32.86 | 83.59 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.